New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
10:51 EDTAPRIApricus Biosciences upgraded to Buy from Hold at Cantor
Cantor Fitzgerald upgraded Apricus Biosciences to Buy citing potential upcoming pipeline catalysts. The firm raised its price target for shares to $3 from $2.50.
News For APRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
12:43 EDTAPRIApricus Biosciences downgraded to Hold from Buy at Cantor
Cantor Fitzgerald downgraded Apricus Biosciences to Hold and lowered its price target for shares to $1.50 from $3 citing the dilutive equity sale to Aspire Capital.
October 20, 2014
06:13 EDTAPRIApricus Biosciences to host conference call
Subscribe for More Information
05:27 EDTAPRIApricus licensed U.S. development, commercialization rights for fispemifene
Apricus Biosciences announced that it has licensed the U.S. development and commercialization rights for a novel selective estrogen receptor modulator, or SERM, fispemifene, an investigational treatment for urological conditions in men, from Forendo Pharma, a private therapeutics company based in Finland. This license agreement combines Apricus' expertise in men's health with Forendo's established leadership in SERM drug discovery, to advance the development of fispemifene as an investigational treatment for urological conditions in men. Under the terms of the agreement, Forendo and its advisors received an upfront license fee of $12.5M comprised of a $5M cash payment and the issuance of $7.5M in Apricus common stock; approximately 3.6M shares priced at the 360-day average market price of $2.08 per share. The agreement includes additional potential clinical and regulatory milestone payments to Forendo of up to $45M, including for potential FDA approval, as well as potential commercial milestone payments totaling up to $260M, based on achieving specified annual net sales levels up to $1B in the U.S. Apricus will also pay tiered low double-digit royalties based on net sales once the product is commercialized. Apricus will be responsible for the clinical development of fispemifene in the U.S., as well as all future commercialization efforts in the U.S. and its territories.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use